Promising Remissions in Relapsed Refractory Classical Hodgkin Lymphoma Patients Requiring Multiple Salvage Regimens Before Transplantation in the Brentuximab Vedotin Era

Overview

Journal Leuk Res Rep

Date 2021 Nov 22

PMID 34804792

Citations 1

Authors

Khadega A Abuelgasim

Samer Ghazi

Bader Alahmari

Ayman Alhejazi

Ahmed Alaskar

Mohsen Alzahrani

Moussab Damlaj

Affiliations

Soon will be listed here.

Abstract

Relapsed/refractory classical Hodgkin lymphoma (R/R cHL) patients refractory to first line salvage have poor outcomes. Herein we report the outcome of R/R cHL patients requiring ≥two vs. one line in the era of chemo-immunotherapy. Among 55 R/R cHL patients, 33 (60%) required one, 22 (40%) required ≥two lines. At 2 years, the estimated PFS and OS for patients requiring one vs. ≥two lines was 71.2% (50.1-84.7) vs. 51.9% (27.6-71.6), = 0.16 and 84.6% (63-94) vs. 84% (58-95), = 0.88, respectively. Patients requiring ≥two salvage lines prior to HCT can achieve comparable outcomes to those requiring one, possibly due to brentuximab vedotin leading to higher CMR rates.

Citing Articles

ROLE OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN RELAPSED/ REFRACTORY HODGKIN'S LYMPHOMA: RETROSPECTIVE DATA FROM A TERTIARY CARE CENTRE IN INDIA.

Suseela Murugesan M, Perumal Kalaiyarasi J, Mehra N, Karunakaran P, Radhakrishnan V, Kannan K Blood Cell Ther. 2025; 8(1):138-146.

PMID: 40061179 PMC: 11883480. DOI: 10.31547/bct-2024-011.

Treatment Patterns and Clinical Outcomes in Patients with Hodgkin Lymphoma from Saudi Arabia, Türkiye, and South Africa: Subgroup Analysis from the International Multicenter Retrospective B-HOLISTIC Study.

Brittain D, Akhtar S, Rodrigues S, Patel M, Moodley D, Singh J Turk J Haematol. 2024; 41(4):211-224.

PMID: 39463021 PMC: 11628755. DOI: 10.4274/tjh.galenos.2024.2024.0181.

References

Linch D, Winfield D, Goldstone A, Moir D, Hancock B, McMillan A . Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet. 1993; 341(8852):1051-4. DOI: 10.1016/0140-6736(93)92411-l. View

Garcia-Sanz R, Sureda A, de la Cruz F, Canales M, Gonzalez A, Pinana J . Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group). Ann Oncol. 2019; 30(4):612-620. DOI: 10.1093/annonc/mdz009. View

Brandwein J, Callum J, Sutcliffe S, Scott J, Keating A . Evaluation of cytoreductive therapy prior to high dose treatment with autologous bone marrow transplantation in relapsed and refractory Hodgkin's disease. Bone Marrow Transplant. 1990; 5(2):99-103. View

Moskowitz C, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi M . Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015; 385(9980):1853-62. DOI: 10.1016/S0140-6736(15)60165-9. View

Moskowitz A, Yahalom J, Kewalramani T, Maragulia J, Vanak J, Zelenetz A . Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood. 2010; 116(23):4934-7. PMC: 3799204. DOI: 10.1182/blood-2010-05-282756. View

Maly J, Alinari L . Pembrolizumab in classical Hodgkin's lymphoma. Eur J Haematol. 2016; 97(3):219-27. PMC: 4987237. DOI: 10.1111/ejh.12770. View

Kuruvilla J, Nagy T, Pintilie M, Tsang R, Keating A, Crump M . Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell.... Cancer. 2005; 106(2):353-60. DOI: 10.1002/cncr.21587. View

Moskowitz C, Walewski J, Nademanee A, Masszi T, Agura E, Holowiecki J . Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018; 132(25):2639-2642. DOI: 10.1182/blood-2018-07-861641. View

Van Heertum R, Scarimbolo R, Wolodzko J, Klencke B, Messmann R, Tunc F . Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trials. Drug Des Devel Ther. 2017; 11:1719-1728. PMC: 5479259. DOI: 10.2147/DDDT.S136988. View

10.

Perales M, Ceberio I, Armand P, Burns L, Chen R, Cole P . Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2015; 21(6):971-83. DOI: 10.1016/j.bbmt.2015.02.022. View

11.

Adams H, Kwee T . Prognostic value of pretransplant FDG-PET in refractory/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis. Ann Hematol. 2016; 95(5):695-706. PMC: 4819743. DOI: 10.1007/s00277-016-2619-9. View

12.

Novakovic B . Checkpoint inhibitors in Hodgkin's lymphoma. Eur J Haematol. 2015; 96(4):335-43. DOI: 10.1111/ejh.12697. View

13.

Hahn T, McCarthy P, Carreras J, Zhang M, Lazarus H, Laport G . Simplified validated prognostic model for progression-free survival after autologous transplantation for hodgkin lymphoma. Biol Blood Marrow Transplant. 2013; 19(12):1740-4. PMC: 3906436. DOI: 10.1016/j.bbmt.2013.09.018. View

14.

Bartlett N, Niedzwiecki D, Johnson J, Friedberg J, Johnson K, Van Besien K . Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol. 2007; 18(6):1071-9. DOI: 10.1093/annonc/mdm090. View

15.

LaCasce A, Bociek R, Sawas A, Caimi P, Agura E, Matous J . Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood. 2018; 132(1):40-48. PMC: 6073588. DOI: 10.1182/blood-2017-11-815183. View

16.

Ansell S, Lesokhin A, Borrello I, Halwani A, Scott E, Gutierrez M . PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2014; 372(4):311-9. PMC: 4348009. DOI: 10.1056/NEJMoa1411087. View

17.

Damlaj M, Ghazi S, Syed G, Pasha T, Gmati G, Salama H . Pre-autologous transplantation PET/CT using Deauville criteria is an independent predictor of progression in relapsed refractory classical Hodgkin lymphoma. Bone Marrow Transplant. 2017; 52(9):1342-1344. DOI: 10.1038/bmt.2017.143. View

18.

Moskowitz C, Bertino J, Glassman J, Hedrick E, Hunte S, Agus D . Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol. 1999; 17(12):3776-85. DOI: 10.1200/JCO.1999.17.12.3776. View

19.

Advani R, Moskowitz A, Bartlett N, Vose J, Ramchandren R, Feldman T . Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. Blood. 2021; 138(6):427-438. DOI: 10.1182/blood.2020009178. View

20.

Villa D, Seshadri T, Puig N, Massey C, Tsang R, Keating A . Second-line salvage chemotherapy for transplant-eligible patients with Hodgkin's lymphoma resistant to platinum-containing first-line salvage chemotherapy. Haematologica. 2011; 97(5):751-7. PMC: 3342979. DOI: 10.3324/haematol.2011.047670. View